EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Vinod K Viswanathan, Aloke G Ghoshal, Anant Mohan, Ketaki Patil, Chaitanya Bhargave, Sanjay Choudhari, Suyog Mehta

Pulmonary Therapy · 2024-12 · 10 (4) · 377-409

DOI: 10.1007/s41030-024-00271-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pulmonary Therapy, online erschienen am 28.09.2024. Verfasst von Vinod K Viswanathan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Thoracic Medicine, Madras Medical College, Chennai, India. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A severe and progressive interstitial lung disease (ILD) known as idiopathic pulmonary fibrosis (IPF) has an unknown etiology with poorly defined mechanisms of development. Among the currently prescribed pharmacological interventions for IPF, nintedanib demonstrates the ability to decelerate the deterioration of lung function and yield positive clinical outcomes. Multiple randomized placebo-controlled trials have confirmed the efficacy and acceptable safety profile of nintedanib. Real-world evidence studies also support the use of nintedanib in IPF, being an efficient and well-tolerated treatment option. It has the potential to stabilize the disease progression in patients with ILD. Patients with IPF frequently have comorbidities like diabetes and hypertension, which can exacerbate the course of disease, reduce quality of life, and decrease treatment adherence. For well-informed decision-making, it is important for healthcare professionals to recognize the position of nintedanib therapy in IPF with comorbidities. The gastrointestinal adverse effects, notably diarrhea, dominate the nintedanib safety profile. These can be effectively controlled by closely monitoring side effects, administering anti-diarrheal and anti-emetic drugs, reducing the nintedanib dose, and discontinuing it in case of severe symptoms with an option to reintroduce the treatment after side effects subside. Symptomatic interventions and monitoring of liver enzymes may reduce the occurrence of permanent treatment discontinuations.

Schlagwörter

Stichwörter der Autor:innen

Adverse effectsAntifibroticForced vital capacityGastrointestinalIdiopathic pulmonary fibrosisNintedanib

Autor:innen und Institutionen

  • Institute of Thoracic Medicine, Madras Medical College, Chennai, India.
  • National Allergy Asthma Bronchitis Institute, Kolkata, West Bengal, India.
  • Department of Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Medical Affairs & Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India. Ketaki.patil1@sunpharma.com.
  • Medical Affairs & Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India.

Zitieren

APA

Viswanathan, V. K., Ghoshal, A. G., Mohan, A., Patil, K., Bhargave, C., Choudhari, S., & Mehta, S. (2024). Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 10(4), 377-409. https://doi.org/10.1007/s41030-024-00271-1

Vancouver

Viswanathan VK, Ghoshal AG, Mohan A, Patil K, Bhargave C, Choudhari S, et al. Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy. 2024;10(4):377-409. doi:10.1007/s41030-024-00271-1

BibTeX
@article{Viswanathan2024,
  author = {Viswanathan, Vinod K and Ghoshal, Aloke G and Mohan, Anant and Patil, Ketaki and Bhargave, Chaitanya and Choudhari, Sanjay and Mehta, Suyog},
  title = {Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis},
  journal = {Pulmonary Therapy},
  year = {2024},
  volume = {10},
  number = {4},
  pages = {377--409},
  doi = {10.1007/s41030-024-00271-1}
}
Kostenlos starten →